http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#Head http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#assertion http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#provenance http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#pubinfo http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#assertion http://purl.obolibrary.org/obo/DOID_3459 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_3459 http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01229 http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#association http://www.w3.org/2000/01/rdf-schema#label paclitaxel injection usp is indicated as first line and subsequent therapy for the treatment of advanced carcinoma of the ovary as first line therapy paclitaxel injection usp is indicated in combination with cisplatin paclitaxel injection usp is indicated for the adjuvant treatment of node positive breast cancer administered sequentially to standard doxorubicin containing combination chemotherapy in the clinical trial there was an overall favorable effect on disease free and overall survival in the total population of patients with receptor positive and receptor negative tumors but the benefit has been specifically demonstrated by available data median follow up 3 months only in the patients with estrogen and progesterone receptor negative tumors see clinical studies breast carcinoma paclitaxel injection usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy prior therapy should have included an anthracycline unless clinically contraindicated paclitaxel injection usp in combination with cisplatin is indicated for the first line treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and or radiation therapy paclitaxel injection usp is indicated for the second line treatment of aids related kaposi s sarcoma http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01229 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#provenance http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#pubinfo http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#sig http://purl.org/nanopub/x/hasSignature ZbY8DCjMl5voCpCJeQ56q8/nHg5iXDXMmFkTkHInQJf+G3NnFeolyfPm+gvxelOa2wIeJru3UC+E/VzhbunDQcWJq5Tgl1pztnLRbmedjnjLuLeviynaTFg9OYutwgEUGDVcGRy7cYSib6BKjDHktJ/zUEmig+VwOUB2cVw1HUc= http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw http://purl.org/dc/terms/created 2021-06-29T08:21:27.488+02:00 http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAANK7OdLowZOYXri1eTPlpHy_Ebbo1QpEK6qxLO8uUQw https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs